Clinical trial NCT02128321: A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine
Official title: A Phase 1 Open Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Pharmacokinetics of Repaglinide
Pharmacokinetics of Caffeine
Healthy Subjects
Keywords: Isavuconazole
Repaglinide
Caffeine
BAL4815
BAL8728
Healthy Subjects
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
Collaborators: name: Basilea Pharmaceutica International Ltd
First posted: 2014-05-01
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to assess the effect of multiple doses of isavuconazole on the pharmacokinetics of Repaglinide and possible metabolites after single dose administration. In addition, this study will assess the effect of multiple doses of isavuconazole on the pharmacokinetics of caffeine and possible metabolites after single dose administration. Safety and tolerability of isavuconazole alone and in combination with Repaglinide or in combination with caffeine will be assessed.


Eligibility criteria: Inclusion Criteria:

* The subject has a body weight of at least 50 kg and a body mass index of 18.5 to 32 kg/m2, inclusive
* The subject's 12-lead electrocardiogram (ECG) is normal
* The subject's clinical laboratory test results are within normal limits

Exclusion Criteria:

* The subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or malignancy
* Female subject has been pregnant within 6 months before screening or breast feeding within 3 months before screening
* The subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmia or torsade de pointes, structural heart disease, or family history of either Short or Long QT syndrome (suggested by sudden death of a close relative at a young age due to possible or probable cardiac causes). QT is the time between the start of the Q wave and the end of the T wave in the heart's electrical system
* The subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to clinic admission
* The subject has received a vaccination within the last 30 days prior to study drug administration
* The subject has a positive serology test for Hepatitis B surface antigen (HBsAg), Hepatitis A Immunoglobulin M antibody (anti HAV (IgM)), Hepatitis C antibody (anti-HCV), or human immunodeficiency virus (anti-HIV 1+2)
* The subject has a known or suspected allergy to any of the components of the trial products or the azole class of compounds, or a history of multiple and/or severe allergies to drugs or foods, or a history of severe anaphylactic reactions
* The subject has used tobacco or nicotine containing products in the last 6 months
* The subject has had treatment with any prescribed or non-prescribed drugs (including vitamins, natural and herbal remedies, e.g. St. John's wort) in the 2 weeks prior with the exception of hormonal methods of contraception, hormone replacement therapy, or occasional use of acetaminophen up to 2 g/day
* The subject has participated in any interventional clinical study or has received any investigational drugs within past 30 days or 5 half-lives, whichever is longer
* The subject has had any significant blood loss, donated one unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to clinic admission
* The subject anticipates an inability to abstain from alcohol or caffeine use for 48 hours prior and throughout the duration of the study; or from grapefruit, grapefruit juice, star fruit, or Seville oranges or any products containing these items from 72 hours prior and throughout the duration of the study
* The subject has history of consuming more than 14 units of alcoholic beverages per week within 6 months prior to screening or has a history of alcoholism or drug/chemical/substance abuse within past 2 years prior to screening (Note: one unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits/hard liquor) or the subject tests positive for alcohol or drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, and opiates)
* The subject has taken part in strenuous exercise within 3 days before Day 1

Primary outcomes:
measure: Pharmacokinetics of plasma repaglinide and possible metabolite concentration: Area under the concentration-time curve from time of dosing to the last quantifiable concentration (AUClast)
timeFrame: Days 1 and 14
measure: Pharmacokinetics of plasma repaglinide and possible metabolite concentration: Area under the concentration-time curve from time 0 extrapolated to infinity (AUCinf)
timeFrame: Days 1 and 14
measure: Pharmacokinetics of plasma repaglinide and possible metabolite concentration: Maximum concentration (Cmax)
timeFrame: Days 1 and 14
measure: Pharmacokinetics of caffeine and possible metabolite concentration: Area under the concentration-time curve from time of dosing to the last quantifiable concentration (AUClast)
timeFrame: Days 3 and 16
measure: Pharmacokinetics of caffeine and possible metabolite concentration: Area under the concentration-time curve from time 0 extrapolated to infinity (AUCinf)
timeFrame: Days 3 and 16
measure: Pharmacokinetics of caffeine and possible metabolite concentration: Maximum concentration (Cmax)
timeFrame: Days 3 and 16
measure: Pharmacokinetics of plasma isavuconazole concentration: Trough concentration (Ctrough)
timeFrame: Days 10-18
measure: Pharmacokinetics of plasma isavuconazole concentration: Area under the concentration-time curve during the time interval between consecutive dosing (AUCtau)
timeFrame: Days 13, 14 and 16
measure: Pharmacokinetics of plasma isavuconazole concentration: Maximum concentration (Cmax)
timeFrame: Days 13, 14 and 16
measure: Pharmacokinetics of plasma isavuconazole concentration: Time after dosing when Cmax occurs (tmax)
timeFrame: Days 13, 14 and 16
measure: Safety assessed through adverse events
timeFrame: up to Day 24
measure: Safety assessed through clinical laboratory evaluations
timeFrame: up to Day 18
measure: Safety assessed by 12-lead electrocardiograms (ECGs)
timeFrame: up to Day 18
measure: Safety assessed through vital signs
timeFrame: up to Day 18
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Parexel Early Phase Clinical Unit
state: Maryland
Study officials:
affiliation: Astellas Pharma Global Development, Inc.
name: Senior Medical Director
role: STUDY_DIRECTOR
References: